Jefferies analyst Michael Yee last night downgraded Spark Therapeutics (ONCE) to Hold while raising his price target for the shares to $114.50 from $85. He believes the buyout by Roche (RHHBY) will close as expected, by Q2. Further, the analyst sees the deal as positive for other gene and cell therapy names, “as interest from large biopharma should persist as the technology matures.”
https://thefly.com/landingPageNews.php?id=2870339
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.